Cargando…
Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation
Green tea is manufactured from the leaves of Camellia sinensis and has been shown to possess, among other properties, anticancer, antiobesity, antiatherosclerotic, antidiabetic, antibacterial, and antiviral effects. The beneficial effects of green tea are related to the activities of (−)-epigallocat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096752/ https://www.ncbi.nlm.nih.gov/pubmed/27826184 http://dx.doi.org/10.2147/DDDT.S109589 |
_version_ | 1782465518779760640 |
---|---|
author | Frias, Iúri Neves, Ana Rute Pinheiro, Marina Reis, Salette |
author_facet | Frias, Iúri Neves, Ana Rute Pinheiro, Marina Reis, Salette |
author_sort | Frias, Iúri |
collection | PubMed |
description | Green tea is manufactured from the leaves of Camellia sinensis and has been shown to possess, among other properties, anticancer, antiobesity, antiatherosclerotic, antidiabetic, antibacterial, and antiviral effects. The beneficial effects of green tea are related to the activities of (−)-epigallocatechin gallate (EGCG). This catechin is very unstable, undergoing degradation and epimerization, which is responsible for the loss of its health benefits. Encapsulation in nanoparticles (NPs) is an effective method to protect EGCG from adverse environmental conditions. In this work, solid lipid NPs (SLN) and nanostructured lipid carriers (NLC) were successfully developed to be used as biocompatible nanocarriers, enhancing the stability of EGCG. The mean diameter of the NPs was found to be around 300–400 nm, which is suitable for oral administration. Moreover, EGCG was effectively encapsulated with a remarkable efficiency of encapsulation of 80% and 90% for SLN and NLC, respectively. In addition, high storage stability of the formulations is expected as they maintain the initial characteristics for 3 months. Limited release of EGCG from the NPs was observed in simulated gastric and intestinal fluids. MTT and lactate dehydrogenase (LDH) assays demonstrated that NPs possess low toxicity, and so have potential to be used for preventive and therapeutic EGCG supplementation. |
format | Online Article Text |
id | pubmed-5096752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50967522016-11-08 Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation Frias, Iúri Neves, Ana Rute Pinheiro, Marina Reis, Salette Drug Des Devel Ther Original Research Green tea is manufactured from the leaves of Camellia sinensis and has been shown to possess, among other properties, anticancer, antiobesity, antiatherosclerotic, antidiabetic, antibacterial, and antiviral effects. The beneficial effects of green tea are related to the activities of (−)-epigallocatechin gallate (EGCG). This catechin is very unstable, undergoing degradation and epimerization, which is responsible for the loss of its health benefits. Encapsulation in nanoparticles (NPs) is an effective method to protect EGCG from adverse environmental conditions. In this work, solid lipid NPs (SLN) and nanostructured lipid carriers (NLC) were successfully developed to be used as biocompatible nanocarriers, enhancing the stability of EGCG. The mean diameter of the NPs was found to be around 300–400 nm, which is suitable for oral administration. Moreover, EGCG was effectively encapsulated with a remarkable efficiency of encapsulation of 80% and 90% for SLN and NLC, respectively. In addition, high storage stability of the formulations is expected as they maintain the initial characteristics for 3 months. Limited release of EGCG from the NPs was observed in simulated gastric and intestinal fluids. MTT and lactate dehydrogenase (LDH) assays demonstrated that NPs possess low toxicity, and so have potential to be used for preventive and therapeutic EGCG supplementation. Dove Medical Press 2016-10-31 /pmc/articles/PMC5096752/ /pubmed/27826184 http://dx.doi.org/10.2147/DDDT.S109589 Text en © 2016 Frias et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Frias, Iúri Neves, Ana Rute Pinheiro, Marina Reis, Salette Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation |
title | Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation |
title_full | Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation |
title_fullStr | Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation |
title_full_unstemmed | Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation |
title_short | Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation |
title_sort | design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096752/ https://www.ncbi.nlm.nih.gov/pubmed/27826184 http://dx.doi.org/10.2147/DDDT.S109589 |
work_keys_str_mv | AT friasiuri designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation AT nevesanarute designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation AT pinheiromarina designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation AT reissalette designdevelopmentandcharacterizationoflipidnanocarriersbasedepigallocatechingallatedeliverysystemforpreventiveandtherapeuticsupplementation |